Wegovy self-pay prices settle at $349 for pens and $399 for the high dose

Novo Nordisk's published cash-pay prices for Wegovy (semaglutide) have settled into a clear tier structure: $349 a month for the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg pens, and $399 a month for the Wegovy HD 7.2 mg pen ^[1][2]. Wegovy tablets are priced separately by dose, from $149 to $299 a month ^[2].

The $349 and $399 figures are what the company calls the "standard offer" — the price that applies after a limited-time introductory discount runs out. Under that introductory offer, patients new to the Wegovy Savings Offer or NovoCare Pharmacy pay $199 a month for the 0.25 mg and 0.5 mg starting doses, good for two monthly fills through December 31, 2026 ^[1][2]. After those two fills, the standard prices take over ^[2].

What the numbers cover

For the pens, Novo defines one month as one box of four pens ^[1][2]. For tablets, one month is one bottle of 30 tablets ^[1][2]. Self-pay prices are available either through local pharmacy pickup with the savings offer or through home delivery from NovoCare Pharmacy, which the site lists as free shipping ^[1][2].

The oral version is cheaper at lower doses. Wegovy pill pricing is $149 a month for 1.5 mg, $199 for 4 mg, and $299 for both 9 mg and 25 mg ^[1][2]. That means the top two tablet strengths cost the same, and the highest tablet dose still lands $50 below the $349 pen price ^[2].

People with commercial insurance are pointed to a different path. The savings offer advertises "as little as $25" a month for Wegovy pills, Wegovy pens and the Wegovy HD pen, but that discount is capped at a maximum savings of $100 per month ^[1][2]. Government beneficiaries — including people on Medicare and Medicaid — are excluded, and the copay savings route is only available for local pharmacy pickup, not home delivery ^[2]. Eligibility and other restrictions apply, and Novo Nordisk states it can modify or cancel the programs at any time ^[1][2].

The $100 monthly savings cap matters for anyone doing the math. It means the $25 figure only applies when insurance already covers most of the cost; if a plan leaves a larger share to the patient, the card reduces that amount by up to $100 and no more ^[1][2].

Why it matters for patients

For people paying cash, the practical takeaway is that the starting price and the ongoing price are different numbers. A new patient beginning at 0.25 mg pays $199 for the first two monthly fills, then $349 once the introductory window closes ^[1][2]. Someone who later moves to the 7.2 mg high-dose pen would see the monthly cost rise again to $399 ^[1][2]. Over a year, the difference between the tablet entry price of $149 and the HD pen at $399 is substantial — $250 a month, or $3,000 a year, based on the posted prices ^[2].

The pricing also creates a split between insured and uninsured pathways. Commercially insured patients using the savings card may pay far less than the cash price, but only at a retail pharmacy and only if their plan covers the drug at all ^[2]. People with Medicare or Medicaid are not eligible for the $25 offer and would be looking at either their plan's coverage rules or the self-pay prices ^[2].

The sources here are Novo Nordisk's own NovoCare pricing page and its downloadable price guide ^[1][2]. They do not state Wegovy's list price, what insurers actually pay, or how these self-pay prices compare with competing GLP-1 products. Whether prices will hold beyond the stated offer periods is also not known; the terms say the company reserves the right to change the programs ^[1][2].

What happens next

The key dated milestone is December 31, 2026 — the end of the limited-time $199 offer for the first two monthly fills of the 0.25 mg and 0.5 mg pens for new patients ^[1][2]. After that date, or after two fills, whichever comes first, the standard $349 and $399 prices apply ^[2]. No other expiration dates are listed for the tablet prices or the $25 commercial copay offer in the published materials ^[1][2].